
Sign up to save your podcasts
Or


Send us a text
Surfing NASH delivered a second wrap-up session on-site in Vienna as a part of its real-time coverage of a truly thought-provoking EASL Congress 2023. This conversation held after the Saturday late breakers features key opinion leaders Hannes Hagström and Michelle Long, entrepreneur and epigenetics advocate Rachel Zayas and patient advocates Jeff McIntyre and Michael Betel alongside host Roger Green. The discussion picks up on the topic of the announced MAESTRO-NASH Phase 3 results and the panelists' various reactions. This subject quickly beckons questions around the scoring systems used to evaluate NASH and specifically some shortcomings within the NASH CRN system. The group also anticipates the role that resmetirom will play in both the short and long term and the implications of superior patient support in both arms of the randomized clinical trials and how well the drug will be perceived to work in the treating community.
For a variety of reasons, EASL Congress 2023 has been looked forward to by the liver community with arguably an unprecedented sense of excitement and intensity. The conversations resulting from the podcast’s two real-time reviews suggest that the actual event met or exceeded such high expectations. If you have any question or interests around EASL Congress, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].
Stay Safe and Surf On!
By SurfingNASH.com3.9
2424 ratings
Send us a text
Surfing NASH delivered a second wrap-up session on-site in Vienna as a part of its real-time coverage of a truly thought-provoking EASL Congress 2023. This conversation held after the Saturday late breakers features key opinion leaders Hannes Hagström and Michelle Long, entrepreneur and epigenetics advocate Rachel Zayas and patient advocates Jeff McIntyre and Michael Betel alongside host Roger Green. The discussion picks up on the topic of the announced MAESTRO-NASH Phase 3 results and the panelists' various reactions. This subject quickly beckons questions around the scoring systems used to evaluate NASH and specifically some shortcomings within the NASH CRN system. The group also anticipates the role that resmetirom will play in both the short and long term and the implications of superior patient support in both arms of the randomized clinical trials and how well the drug will be perceived to work in the treating community.
For a variety of reasons, EASL Congress 2023 has been looked forward to by the liver community with arguably an unprecedented sense of excitement and intensity. The conversations resulting from the podcast’s two real-time reviews suggest that the actual event met or exceeded such high expectations. If you have any question or interests around EASL Congress, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].
Stay Safe and Surf On!

32,328 Listeners

30,868 Listeners

9,652 Listeners

106 Listeners

21,256 Listeners

3,374 Listeners

113,056 Listeners

57,023 Listeners

9,578 Listeners

8,701 Listeners

10,264 Listeners

6,464 Listeners

0 Listeners

418 Listeners

671 Listeners